Robert Davidson | CEO and Chairman of the Board of Directors
Prior to his role at CURE Pharmaceutical, Robert Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also attended Post Graduate Studies at the University of Cambridge.
Edward Maliski, PhD | President and Chief Science Officer
Dr. Edward Maliski is an accomplished research scientist with 30 years of experience in the development of pharmaceutical and biotechnology products. As an executive leader and strategist, Maliski contributed his expertise in project management and chemical research to facilitate the transfer of new discoveries into pharmaceutical products for the Sterling Winthrop Research Institute, Glaxo Research Institute, Merck & Co., and Amgen Inc. Additionally, Dr. Maliski has worked with several successful start-up companies.
Wayne Nasby | Chief Operations Officer
As Chief Operating Officer, Wayne leads the executive management team to focus on the development and commercialization of innovative and technically complex pharmaceutical products. Wayne has been recognized by industry and regulatory leaders in cGMP pharmaceutical regulatory compliance and innovation. He has successfully built pharmaceutical manufacturing facilities in Asia, Europe and the United States. With more than 30 years’ experience in the biotechnology and pharmaceutical industry, Wayne has held a variety of roles within the areas of corporate quality, supply chain management, manufacturing, process development and project management. Prior to CURE, he served as Vice President of Operations at Innozen Inc. where he was responsible for commercial manufacturing locations, quality assurance and Innozen’s supply chain. Wayne also served early on in various leadership positions at AMGEN, Inc. where he was instrumental in helping build the industry’s largest Biotechnology company. During his twenty-year tenure at AMGEN, Inc. he was responsible for the distribution and transportation of bulk and commercial biotechnology products within the United States and to Asia, Australia, Europe and Puerto Rico.
Jessica Rousset | Chief Business Officer
As Chief Business Officer, Jessica has responsibility for driving strategy and growth. She is a seasoned business development and commercialization leader, expert in bridging corporate, academic and governmental interests toward the common goal of improving patient’s lives. She brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. Jessica previously served as Head of Innovation at Children’s Hospital Los Angeles, where over a ten year period, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, Jessica held positions at The Scripps Research Institute and GlaxoSmithkline Biologicals in laboratory, clinical research and business development roles. She trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.
Mark Udell | Chief Financial Officer
Mark Udell has served as the Chief Financial Officer, Treasurer and Secretary of CURE Pharmaceutical since July 2011. He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to Cure Pharmaceutical, Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.
Eric E. Allen, PhD | Director of Research and Development
Dr. Eric Allen brings over 25 years of pharmaceutical industry experience to CURE Pharmaceutical. Allen spent 10 years at Merck & Co, where he synthesized and patented heterocyclic drug molecules. He later devoted himself to chemical information management for Amgen Inc., where he was involved in all aspects of scientific database and software design. Allen is a recognized expert in the pharmaceutical industry for his programming, design, and insight in the drug discovery field, and is an inventor on 16 drug-related, issued U.S. patents.
Richard Serbin | Director of Corporate Development
Mr. Richard S. Serbin is a global strategy advisor and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and patent attorney in the healthcare industry. Mr. Serbin is an expert in licensing medical extracts, compounds, and technologies. He is a pharmacist and patent attorney with more than 25 years of experience in the pharmaceutical industry and the investment community. Mr. Serbin spent a large portion of his career focusing on international markets and clients.